MedPath

Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Phase 1
Active, not recruiting
Conditions
Metastatic Lung Cancer
Non Small Cell Lung Cancer
Advanced Cancer
Squamous Cell Lung Cancer
Non-Squamous Non-Small Cell Neoplasm of Lung
Lung Cancer
Interventions
Drug: Pirfenidone
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
First Posted Date
2017-06-06
Last Posted Date
2024-11-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
48
Registration Number
NCT03177291
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Phase 2
Withdrawn
Conditions
Lung Cancer
Interventions
Drug: Apatinib
Drug: Pemetrexed
Drug: Carboplatin
First Posted Date
2017-05-24
Last Posted Date
2024-12-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
128
Registration Number
NCT03164694
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2
Active, not recruiting
Conditions
Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage I Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Interventions
Biological: Ipilimumab
Drug: Carboplatin
Drug: Cisplatin
Biological: Nivolumab
Drug: Docetaxel
Drug: Pemetrexed
First Posted Date
2017-05-17
Last Posted Date
2024-06-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
101
Registration Number
NCT03158129
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: NKTR-214
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Atezolizumab
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
First Posted Date
2017-05-03
Last Posted Date
2023-03-10
Lead Sponsor
Nektar Therapeutics
Target Recruit Count
162
Registration Number
NCT03138889
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇩🇪

Lungenklinik Hemer, Hemer, Germany

🇺🇸

Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States

and more 35 locations

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3
Completed
Conditions
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Respiratory Tract Disease
Thoracic Neoplasms
Lung Diseases
Neoplasms by Site
Neoplasm, Bronchial
Carcinoma, Bronchogenic
Interventions
Biological: SHR-1210
Drug: Carboplatin
Drug: Pemetrexed
First Posted Date
2017-05-01
Last Posted Date
2020-06-09
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
419
Registration Number
NCT03134872
Locations
🇨🇳

Tongji University, Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2
Completed
Conditions
Recurrent Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC V8
Stage III Lung Cancer AJCC V8
Unresectable Lung Non-Small Cell Carcinoma
Interventions
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2017-04-28
Last Posted Date
2024-12-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
18
Registration Number
NCT03132532
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer

Phase 1
Completed
Conditions
Leptomeningeal Metastases
Interventions
Drug: Pemetrexed
Drug: Dexamethasone
Drug: Folic Acid
Drug: Vitamin B12
First Posted Date
2017-04-05
Last Posted Date
2019-03-19
Lead Sponsor
The First Hospital of Jilin University
Target Recruit Count
13
Registration Number
NCT03101579
Locations
🇨🇳

The First Hospital of Jilin University, Changchun, Jilin, China

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3
Active, not recruiting
Conditions
Lung Carcinomas, Non-Small-Cell
Non-small-cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Carcinoma，Non-Small-Cell Lung
Interventions
Drug: Pemetrexed
Drug: cemiplimab
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
First Posted Date
2017-03-23
Last Posted Date
2024-06-18
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
712
Registration Number
NCT03088540
Locations
🇺🇦

Clinical Study Site 2, Kyiv, Ukraine

🇹🇷

Clinical Study Site 3, İzmir, Turkey

🇧🇷

Clinical Study Site #3, São Paulo, Brazil

and more 9 locations

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2
Completed
Conditions
Colo-rectal Cancer
Interventions
Drug: Pemetrexed
Drug: Tarceva 100Mg Tablet
First Posted Date
2017-03-22
Last Posted Date
2022-06-15
Lead Sponsor
Samsung Medical Center
Target Recruit Count
29
Registration Number
NCT03086538
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

First Posted Date
2017-03-21
Last Posted Date
2022-09-23
Lead Sponsor
Incyte Corporation
Target Recruit Count
70
Registration Number
NCT03085914
Locations
🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 12 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy